Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average Price Target from Brokerages

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $10.80.

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Regulus Therapeutics in a research note on Wednesday, February 26th.

Regulus Therapeutics Price Performance

NASDAQ RGLS opened at $1.29 on Monday. The business’s fifty day moving average is $1.30 and its 200-day moving average is $1.47. The stock has a market capitalization of $84.50 million, a price-to-earnings ratio of -1.21 and a beta of 1.42. Regulus Therapeutics has a one year low of $0.83 and a one year high of $3.79.

Insider Transactions at Regulus Therapeutics

In related news, CEO Joseph P. Hagan sold 115,290 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $145,265.40. Following the completion of the transaction, the chief executive officer now directly owns 222,572 shares of the company’s stock, valued at approximately $280,440.72. This trade represents a 34.12 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Preston Klassen sold 31,445 shares of the business’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $1.26, for a total transaction of $39,620.70. Following the sale, the insider now directly owns 36,055 shares in the company, valued at $45,429.30. The trade was a 46.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 223,998 shares of company stock worth $282,237 over the last quarter. Corporate insiders own 4.35% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. NEA Management Company LLC purchased a new stake in shares of Regulus Therapeutics in the third quarter worth about $10,154,000. Millennium Management LLC lifted its stake in Regulus Therapeutics by 69.7% in the 4th quarter. Millennium Management LLC now owns 2,192,158 shares of the biopharmaceutical company’s stock worth $3,464,000 after purchasing an additional 900,743 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in Regulus Therapeutics in the 3rd quarter worth approximately $1,403,000. Octagon Capital Advisors LP boosted its holdings in Regulus Therapeutics by 13.7% in the 4th quarter. Octagon Capital Advisors LP now owns 4,848,802 shares of the biopharmaceutical company’s stock valued at $7,661,000 after purchasing an additional 585,101 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Regulus Therapeutics during the 3rd quarter valued at $204,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.